René Russo, Xilio CEO (Alicia Petitti for Xilio)
Xilio Therapeutics goes public as biopharma IPOs rumble forward in Q4
It’s been a busy fall on Wall Street — and this week, we’ve got another biotech going public after Ventyx yesterday.
Massachusetts solid-tumor biotech Xilio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
